Neoadjuvant chemo affects PSA levels post-RP, but histology is unchanged

Weekly neoadjuvant chemotherapy with docetaxel (Taxotere) achieved aPSA response in almost 80% of a small group of high-risk prostate cancerpatients enrolled in a feasibility study of single-agent therapy.